Marathon Sells Emflaza to PTC Therapeutics

20.03.2017 - US drugmaker Marathon Pharmaceuticals has sold all rights to its Duchenne muscular dystrophy (DMD) drug Emflaza (deflazacort) to PTC Therapeutics in a deal that could be...